Key Highlights
- The company raised full-year 2026 adjusted EPS guidance to $5.45-$5.60 from $5.38-$5.58.
- Abbott’s adjusted EPS of $1.31 topped analyst expectations by two cents, a modest but meaningful beat that underscores the company’s ability to manage costs amid uneven demand across segments.
- Investors will turn their attention to Abbott’s TECTONIC U.S. key trial, which completed enrollment in April and is evaluating the company’s investigational Coronary Intravascular Lithotripsy System.
Abbott Laboratories delivered stronger-than-expected second-quarter earnings and lifted its full-year profit outlook, signaling momentum in its medical device and diagnostics businesses despite softness in nutrition.
Profit Beat Fuels Guidance Lift
Abbott’s adjusted EPS of $1.31 topped analyst expectations by two cents, a modest but meaningful beat that underscores the company’s ability to manage costs amid uneven demand across segments. The outperformance allowed management to raise its full-year adjusted EPS guidance to a range of $5.45 to $5.60, up from the prior $5.38 to $5.58. Comparable sales growth of 4.8% fell short of the headline 13% figure, which was inflated by currency tailwinds and the inclusion of Exact Sciences, acquired in March.
Still, the guidance revision suggests confidence in a second-half acceleration, particularly in higher-margin medical devices. Nutrition, however, remained a drag, with sales declining 3.1% to $2.144 billion as lower volumes and pricing actions weighed on pediatric and adult products. Established pharmaceuticals posted an 8.4% gain, led by double-digit growth in key emerging markets.
The mixed results highlight Abbott’s reliance on its device portfolio to offset softer areas, a dynamic investors will watch closely as new product launches ramp up. The $155.5 billion company’s ability to return $2.1 billion to shareholders in Q2, through dividends and buybacks, reinforces its commitment to capital allocation even as it invests in growth areas like coronary intravascular lithotripsy and diabetes care. The raised EPS guidance provides a near-term catalyst, but execution in the second half will determine whether the momentum is sustainable.
Next Catalyst: TECTONIC Trial Data
Investors will turn their attention to Abbott’s TECTONIC U.S. key trial, which completed enrollment in April and is evaluating the company’s investigational Coronary Intravascular Lithotripsy System. In the meantime, the company’s pending FDA submission for its Amulet left atrial appendage device and the recent CE Mark for Libre Duo, a dual glucose-ketone sensor, offer additional near-term milestones.
With full-year comparable sales growth still guided at 6.5% to 7.5%, the focus will shift to whether Abbott can deliver on its promise of accelerating earnings in the second half. Based on Abbott’s Q2 2026 results released July 16, 2026.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...